Biopure trial results deflect cover-up accusations
This article was originally published in Clinica
Executive Summary
Biopure has announced that a phase III clinical trial of its blood substitute, Hemopure, has met primary safety and efficacy endpoints. The Cambridge, Massachusetts firm plans to file a marketing application in the US later this year.